---
title: "The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination"
id: "clinicaltrials-nct03878706"
canonical_url: "https://medichelpline.com/clinical-feed/clinicaltrials-nct03878706"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "ClinicalTrials.gov"
source_url: "https://clinicaltrials.gov/study/NCT03878706"
doi: "NCT03878706"
published_at: "2026-03-13T12:00:00.000Z"
evidence_level: "OBSERVATIONAL Trial"
license: "CC-BY-NC-4.0 / Informational Use"
---
# The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/clinicaltrials-nct03878706
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** ClinicalTrials.gov
- **Source URL:** [Original Journal Publication](https://clinicaltrials.gov/study/NCT03878706)
- **DOI:** [NCT03878706](https://doi.org/NCT03878706)
- **Published At:** 2026-03-13T12:00:00.000Z
- **Evidence Rating:** OBSERVATIONAL Trial
## Executive GIST (TL;DR)
RECRUITING · OBSERVATIONAL · Diabetes Mellitus, Type 2 · Enrollment 240 · Sponsor: University of Athens
## Clinical Analysis & Structured Key Points
Official title: The Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination on Endothelial Function, Arterial Stiffness and Left Ventricular Deformation in Patients With Type 2 Diabetes With High Cardiovascular Risk Summary: A. Four groups of patients with type 2 diabetes mellitus with high or very high cardiovascular risk or heart failure with preserved ejection fraction (HFpEF) will be studied before and at 6 and 12 months of treatment: * 60 patients treated with a combination of GLP1 analogue and SGLT2 inhibitor ± metformin * 60 patients treated with GLP-1 agonist as a second step after metformin * 60 patients treated with SGLT2 inhibitor as a second step after metformin * 60 patients treated with a combination of insulin and other antidiabetic agents (metformin - DPP4 inhibitors) Individuals will be equal distributed as far as age, gender and body mass index concerned. In addition, patients suffered from kidney disease and retinopathy are excluded. Conditions: Diabetes Mellitus, Type 2 Keywords: Endothelial glycocalyx integrity, Oxidative stress biomarkers, Arterial stiffness, GLS, NT-proBNP, GDF-15, MOTS-c Study type: OBSERVATIONAL Enrollment: 240 (ESTIMATED) Status: RECRUITING Completion: 2027-06-30 (ESTIMATED)
## Related Clinical Research

- [Healthcare pathways and outcomes for Australians with Coronary Heart Disease and Type 2 Diabetes:](https://medichelpline.com/clinical-feed/pubmed-41849657.md) (DOI: 10.1093/eurjcn/zvag079)
- [Lifestyle Changes May Help Prevent Multimorbidity In Prediabetes](https://medichelpline.com/clinical-feed/medical-news-today-23-diet-weight-loss-and-150-minutes-of-exercise-may-protect-against-chronic.md)
- [Beyond the Scale: What Else Glucagon-like Peptide-1 Receptor Agonists Can Do](https://medichelpline.com/clinical-feed/endocrine-news-34-beyond-the-scale-what-else-glucagon-like-peptide-1-receptor-agonists-can-do.md)
- [GLP-1 Receptor Agonists and Long-Term Pancreatic Cancer Risk: TriNetX Propensity-Matched Analysis](https://medichelpline.com/clinical-feed/pubmed-42745130.md) (DOI: 10.1007/s12029-026-01523-w)
- [NIH awards $4.6M to multi-university team to model hormones and improve women's health](https://medichelpline.com/clinical-feed/endocrine-news-0-nih-awards-multi-university-team-over-4m-to-improve-women-s-health.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.